

Product Datasheet

BP-02501

Catalog No. **BP-02501** · CAS **1637542-33-6** · Form **free base** · Physical state **solid** · Color **Light yellow to yellow** · Version **1.0**
· Revision **2026-09-10**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target DNA-PK; BCRP	Research area Cancer
-------------------------------	--------------------------------

Molecular formula **C₂₄H₂₁ClFN₅O₃**

Molecular weight **481.9070**

STRUCTURE



DESCRIPTION

Nedisertib (Peposertib) is an orally active selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC₅₀ value of less than 3 nM. Nedisertib also acts as a modulator of ABCG2, capable of reversing ABCG2-mediated multidrug resistance (MDR), thus providing new strategies for combination therapy. By inhibiting DNA double-strand break repair, Nedisertib can enhance the efficacy of chemotherapy and radiotherapy. Nedisertib exhibits antitumor activity .

BIOLOGICAL ACTIVITY

Nedisertib (M3814) is a potent, orally available and selective inhibitor of DNA-PK, with an IC₅₀ of <3 nM.

SOLUBILITY

Soluble in DMSO

REFERENCES

- [1]. Wu ZX, et al. M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells. Front Oncol. 2020 May 12;10:674.
- [2]. L. Damstrup, et al. M3814, a DNA-dependent Protein Kinase Inhibitor (DNA-PKi), Potentiates the Effect of Ionizing Radiation (IR) in Xenotransplanted Tumors in Nude Mice. IJROBP. 2016; 94, 940-941.
- [3]. Thomas Fuchss, et al. Arylchinazoline. WO2014183850A1. 2014-11-20.